# Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

> **NCT07403552** · PHASE1 · RECRUITING · sponsor: **Ensho Therapeutics, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** NSHO-101

## Key facts

- **NCT ID:** NCT07403552
- **Lead sponsor:** Ensho Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-31
- **Primary completion:** 2026-03
- **Final completion:** 2026-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07403552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07403552, "Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07403552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*